NCT04159519 - A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions

AsthmaSevere Eosinophilic Asthma

Interventions

DRUG

Symbicort®

Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.

DRUG

Fasenra®

Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.

DRUG

Ventolin®

Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.

Trial Locations (23)

7740

Research Site, Jena

10969

Research Site, Berlin

20354

Research Site, Hamburg

21079

Research Site, Dijon

22767

Research Site, Hamburg

24127

Research Site, Bergamo

29609

Research Site, Brest

30625

Research Site, Hanover

33600

Research Site, Pessac

35043

Research Site, Marburg

53105

Research Site, Bonn

55131

Research Site, Mainz

59000

Research Site, Lille

69317

Research Site, Lyon

80131

Research Site, Napoli

81377

Research Site, München

94270

Research Site, Le Kremlin-Bicêtre

03050

Research Site, Cottbus

00168

Research Site, Roma

BT9 7BL

Research Site, Belfast

CB2 2QQ

Research Site, Cambridge

SE1 9RT

Research Site, London

NG15 1PB

Research Site, Nottingham